CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (INFI) today announced topline data from its Phase 2 study of retaspimycin hydrochloride (HCl), a potent and selective heat shock ...
– Phase 2 Study of Duvelisib with Background Methotrexate in Patients with Moderate-to-Severe Rheumatoid Arthritis Did Not Meet Primary Endpoint – – Infinity to Continue Focusing Its Efforts on the ...
Infinity Pharma INFI announced additional details on the design of its phase II MARIO-8 study, evaluating eganelisib for squamous cell cancer of the head and neck (SCCHN). Shares of the company were ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) (“Infinity”), a clinical-stage biotechnology company developing eganelisib, a ...
Shares of Infinity Pharmaceuticals Inc.INFI rose almost 24% after the company announced that it has entered into a master clinical supply agreement with Roche RHHBY. Per the deal, Roche will supply ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced interim data from its double-blind, randomized, placebo-controlled Phase 2 study comparing saridegib ...
DALLAS — Both the Summit Apex Plus excimer laser and its successor, the Infinity LS system, effectively treat hyperopic astigmatism, according to the results of a multicenter study. “Unlike the Visx ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback